Breast cancer in a male-to-female transsexual patient with a BRCA2 mutation.

  title={Breast cancer in a male-to-female transsexual patient with a BRCA2 mutation.},
  author={Vinciane Corman and Iulia Potorac and Florence Manto and Sarah Dassy and Karin Segers and Albert Thiry and Vincent Bours and Adrian F. Daly and Albert Beckers},
  journal={Endocrine-related cancer},
  volume={23 5},
Breast cancer is rare in male patients. Certain predisposing factors, be they genetic (e.g., BRCA2 gene mutations) or hormonal (imbalance between estrogen and androgen levels), have been implicated in male breast cancer pathophysiology. Male-to-female (MtF) transsexualism is a condition that generally involves cross-sex hormone therapy. Anti-androgens and estrogens are used to mimic the female hormonal environment and induce the cross-sex secondary characteristics. In certain situations, the… 

Figures from this paper

Long-term hormonal therapy resulting in breast cancer in female-to-male transsexual

A rare case of breast cancer in female-to-male transsexual patient after long-term hormonal therapy with a potential risk that testosterone exposure can increase the risk of developing breast cancer by the stimulation of breast tissue.

Breast Cancer Suspicion in a Transgender Male-to-Female Patient on Hormone Replacement Therapy Presenting with Right Breast Mass: Breast Cancer Risk Assessment and Presentation of a Rare Lesion

This case describes a MtF transgender who presented with a breast lesion concerning for malignancy following hormonal replacement therapy, and final pathology revealed lobular hyperplasia in the setting of gynecomastia and pseudoangiomatous stromalhyperplasia (PASH).

Breast Cancer Risk and Screening in Transgender Individuals

The risk of breast cancer development in transgender individuals is different compared to that of the cis-gender population, and further prospective data are needed to appropriately quantify these risks and to assess what is the appropriate breast cancer screening recommendations for this population.

Breast cancer in transgender patients: A systematic review. Part 1: Male to female.

Cancer Screening for Transgender and Gender Diverse Patients

The incidence of sex steroid–influenced cancers among TGD persons appears to be low, but gender-affirming therapies may influence cancer risk, and the patient experience and potential barriers in access should be considered in the development of TGD-specific screening guidelines.

Mammary Myofibroblastoma in a Transgender Patient on Feminizing Hormones: Literature Review and Case Report

The case of a 76-year-old transgender patient who developed an estrogen receptor-positive mammary myofibroblastoma after 13 months of treatment on feminizing hormones is presented, which is the first reported case of MFB occurring in a transgender individual.

Breast cancer in transgender patients: A systematic review. Part 2: Female to Male.

A rare case of breast cancer in a transgender woman

Trans‐counseling: A case series of transgender individuals at high risk for BRCA1 pathogenic variants

The experiences and practices of case preparation, case management, appropriate genetic testing, and medical management such as screening, surgical decisions, and coordination of care are discussed.



Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.

Cross-sex hormone treatment of transsexual subjects does not seem to be associated with an increased risk of malignant breast development, in either MtF or FtM transsexual individuals.

Breast cancer in male-to-female transgender patients: a case for caution.

Breast cancer in male-to-female transsexuals: use of breast imaging for detection.

Screening for breast cancer in male-to-female transsexuals should be undertaken for those with additional risk factors (e.g., family history, BRCA2 mutation, Klinefelter syndrome) and should be available to those who desire screening, preferably in a clinical trial.

Risk of breast cancer in male BRCA2 carriers

The risk of breast cancer for unaffected men who test positive for a BRCA2 mutation is based on very few retrospective studies but this analysis confirmed that breast cancer risk in men was 7.1% ( SE 5.2–8.6%) by age 70 years and 8.4% (SE 6.2-10.6) by age 80  years.

Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature.

  • A. LiedeB. KarlanS. Narod
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
This article reviews studies that estimate risk associated with mutations in BRCA1 or BRCa2, with a focus on the cancer sites most relevant to men, to determine the magnitude of excess cancer risk among BRC a2 carriers and to increase the understanding of the basis for the observed site-specificity in cancer development.

Triple negative breast cancer in a male‐to‐female transsexual

A case of an aggressive triple negative inflammatory breast cancer in a male‐to‐female transsexual with a complicated psychiatric history with significant antipsychotic use is reported.

Male breast cancer: risk factors, diagnosis, and management (Review).

Heightened awareness of the increased risk in certain men by both physicians and patients, and adherence to guidelines recommended for the surveillance of men at increased risk, may result in earlier detection.

Breast cancer in a male-to-female transsexual. A case report.

The clinicopathological findings in a patient who developed breast carcinoma ten years after male-to-female sexual reassignment are reported, and the controversies relating to hormonal influences in the etiology of breast cancer in men are discussed.

Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.

Tumor pathologic features and clinical characteristics examined in 491 women with breast cancer who underwent genetic testing for BRCA mutations suggest that tumors associated with BRCa1 mutations may be divided into two distinct groups, triple-negative and non-triple-negative groups.

Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene.

It is confirmed that BRCA2 is a high-risk prostate-cancer-susceptibility gene and have potential implications for the management of early-onset prostate cancer, in both patients and their relatives.